Zokinvy 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
II/0004 
Update of sections 4.2, 4.4, 4.5 and 6.6 of the SmPC 
14/09/2023 
19/10/2023 
SmPC and PL 
For more information, please refer to the Summary of 
in order to include updated drug-drug interaction 
information based on the final results from Drug-
Drug Interaction study EIG-LNF-021. This is a Phase 
I, open-label, single-centre, two period, single 
sequence study evaluating the effect of 
autoinhibition, and the effects of fluconazole, a non-
specific strong CYP2C9 inhibitor and moderate 
Product Characteristics. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
inhibitor of CYP2C9 and CYP3A, on the multiple-dose 
pharmacokinetics of lonafarnib. The Package Leaflet 
is updated accordingly. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
PSUSA/11005
Periodic Safety Update EU Single assessment - 
08/06/2023 
n/a 
PRAC Recommendation - maintenance 
/202211 
lonafarnib 
IB/0005/G 
This was an application for a group of variations. 
21/04/2023 
n/a 
B.II.z - Quality change - Finished product - Other 
variation 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IAIN/0003 
B.II.b.2.c.1 - Change to importer, batch release 
23/03/2023 
19/10/2023 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0001 
B.I.e.5.b - Implementation of changes foreseen in an 
07/02/2023 
n/a 
approved change management protocol - Requires 
further supportive data 
Page 2/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
